Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping

Clinical Breast Cancer · Published 2026-06-24 · DOI 10.1016/j.clbc.2026.06.014

Authors (3)

Michal Alexovič, Ján Sabo, Pavel Bouchal

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Alexovič, M., Sabo, J., Bouchal, P. (2026). Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.06.014

Related articles

• Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer · Clinical Breast Cancer · 2026 · Same journal
• Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females · Clinical Breast Cancer · 2026 · Same journal
• Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort · Clinical Breast Cancer · 2026 · Same journal
• Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care · Clinical Breast Cancer · 2026 · Same journal
• Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer · Clinical Breast Cancer · 2026 · Same journal
• Association of Regional Anesthesia With Reduced Post-discharge Opioid Prescriptions Following Immediate Autologous Breast Reconstruction: An ACS-NSQIP Analysis · Clinical Breast Cancer · 2026 · Same journal
• Evaluation of Absorbable Hemostatic Powder on Post-operative Outcomes in Patients Undergoing Mastectomy · Clinical Breast Cancer · 2026 · Same journal
• Feasibility of Same Day Mastectomy Discharge in a Safety Net Hospital in Memphis, TN · Clinical Breast Cancer · 2026 · Same journal
• CTSG suppresses breast cancer progression by inhibiting the EGFR/ERK signaling pathway and enhancing CD8⁺ T cell activation · Clinical Breast Cancer · 2026 · Same journal
• The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer · Clinical Breast Cancer · 2026 · Same journal